Location:

Local - Massachusetts

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

Drug Combinations, Combination Therapy, drug synergy, Cancer Treatment, Peter Sorger, independent action, Adam Palmer, Harvard Medical School

“Bet Hedging” Explains the Efficacy of Many Combination Cancer Therapies

iStock-488520877.jpg

Benefits of many cancer drug combinations are not due to drug synergy, but to “bet hedging.” Combinations give each patient multiple chances of responding to at least one drug, increasing survival within patient populations. Findings suggest new ways to improve the design of combination therapies.

Science

Channels:

Data Analysis, Weather And Joint Pain, Medicare records

That Feeling in Your Bones

Unknown.gif

Rainy weather has long been blamed for achy joints and back pain. Past research has yielded mixed results. New analysis tracking visits to the doctor with daily rainfall found no relationship between the two.

Life

Social and Behavioral Sciences

Channels:

Voting, youth voting, Alabama, Senate, US Senate, Doug Jones, Roy Moore, voting behavior, Election, vote

Exclusive Analysis: Role of Young Voters in Alabama U.S. Senate Race

youthvotingAnnaMillerTuftsNow.jpg

Youth turnout in yesterday’s special U.S. Senate election in Alabama is estimated to be 23 percent, according to youth vote experts from the Center for Information and Research on Civic Learning & Engagement (CIRCLE), the preeminent, non-partisan research center on youth engagement at Tufts University’s Jonathan M. Tisch College of Civic Life. Young people were pivotal in tipping the scales for Democratic candidate Doug Jones.

Medicine

Channels:

Dana-Farber/Brigham and Women’s physician wins prestigious 2017 William Dameshek Prize from the American Society of Hematology

• Benjamin Ebert, MD, PhD, current chair of Medical Oncology, was presented with recognition at annual American Society of Hematology meeting • Ebert is notable for his leadership in describing the genomic landscape of adult myelodysplastic syndromes (MDS)

Medicine

Channels:

Study Identifies Agent That Can Reverse Resistance to Targeted Drug in Some Leukemia Cell Types

• Azacitidine reverses resistance to SL-401 in AML and BPDCN cell lines, researchers find • Results prompt clinical trial of SL-401 and azacitidine in AML and MDS patients

Medicine

Science

Channels:

Alzheimer's Disease, clinical trial, Clinical & Translational Research, Dementia

Clinical Trials on Alzheimer’s Disease: Shifting the Focus to Prevention

This past decade, Alzheimer’s science has undergone a paradigm shift toward the disease’s early, silent phase. For trials, this means change at every level: new participants, new screening tools, new outcome measurements. What’s the progress?

Medicine

Channels:

Hematologic Cancers, Leukaemia

Study Shows Combining Chemotherapy with Targeted Drug Boosts Response in Chronic Lymphocytic Leukemia

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.

Medicine

Channels:

Multiple Myeloma, Hematologic Cancers

Sequencing Offers Clues to Progression Toward Multiple Myeloma

Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn’t show outward symptoms.

Medicine

Channels:

multiple myelmoma, Hematologic Cancers

Tracking How Multiple Myeloma Evolves by Sequencing DNA in the Blood

Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments.

Medicine

Channels:

Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder

• Clinical Activity in a Phase 1 Study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis • Study shows one of multiple ways in which novel targeted cancer therapies are now being deployed to improve outcomes and quality of life for patients with rare, advanced, or difficult-to-treat blood malignancies.







Chat now!